Publication number: 20240182456
Abstract: The present invention relates to compounds of formula (I) as activators of glucagon-like peptide 1 (GLP1) receptor for the treatment of obesity, type 2 diabetes mellitus, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, one or more diabetic complications, diabetic nephropathy, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hypertension, atherosclerosis, peripheral arterial disease, stroke, cardiomyopathy, atrial fibrillation, heart failure, coronary heart disease and neuropathy. Preferred compounds are e.g. 2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-imidazole derivatives and similar compounds, such as e.g. C-1, C-2, C-3, C-4 and other compounds.
Type:
Application
Filed:
April 11, 2022
Publication date:
June 6, 2024
Inventors:
Martin ALLAN, Matthew CARSON, Thomas CAYA, Lara CZABANIUK, Ming QIAN, Daniel SMITH, Troy SMITH, Liansheng SU, Chung-Yeh WU, Lihua YANG, Chun ZHANG, Ping ZHANG, Xilin ZHOU